Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) went down by -0.19% from its latest closing price compared to the recent 1-year high of $117.49. The company’s stock price has collected -0.38% of loss in the last five trading sessions. Barron’s reported on 12/13/22 that M&A Could Recover Next Year. These Stocks Could Benefit.
Is It Worth Investing in Horizon Therapeutics Public Limited Company (NASDAQ :HZNP) Right Now?
Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) scored a price-to-earnings ratio above its average ratio, recording 46.39 x from its present earnings ratio. Plus, the 36-month beta value for HZNP is at 1.18. Opinions of the stock are interesting as 2 analysts out of 10 who provided ratings for Horizon Therapeutics Public Limited Company declared the stock was a “buy,” while 0 rated the stock as “overweight,” 8 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $115.50, which is $3.33 above the current price. HZNP currently public float of 223.96M and currently shorts hold a 2.78% ratio of that float. Today, the average trading volume of HZNP was 4.04M shares.
HZNP’s Market Performance
HZNP stocks went down by -0.38% for the week, with a monthly drop of -0.19% and a quarterly performance of 80.18%, while its annual performance rate touched 30.31%. The volatility ratio for the week stands at 0.21% while the volatility levels for the past 30 days are set at 0.26% for Horizon Therapeutics Public Limited Company. The simple moving average for the period of the last 20 days is -0.36% for HZNP stocks with a simple moving average of 34.04% for the last 200 days.
Analysts’ Opinion of HZNP
Many brokerage firms have already submitted their reports for HZNP stocks, with H.C. Wainwright repeating the rating for HZNP by listing it as a “Neutral.” The predicted price for HZNP in the upcoming period, according to H.C. Wainwright is $74 based on the research report published on November 01st of the previous year 2022.
UBS gave a rating of “Buy” to HZNP, setting the target price at $139 in the report published on June 14th of the previous year.
HZNP Trading at 12.95% from the 50-Day Moving Average
After a stumble in the market that brought HZNP to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.98% of loss for the given period.
Volatility was left at 0.26%, however, over the last 30 days, the volatility rate increased by 0.21%, as shares sank -0.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +46.35% upper at present.
During the last 5 trading sessions, HZNP fell by -0.38%, which changed the moving average for the period of 200-days by +4.95% in comparison to the 20-day moving average, which settled at $113.21. In addition, Horizon Therapeutics Public Limited Company saw -0.87% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at HZNP starting from Pasternak Andy, who sale 27,129 shares at the price of $113.03 back on Jan 17. After this action, Pasternak Andy now owns 56,338 shares of Horizon Therapeutics Public Limited Company, valued at $3,066,323 using the latest closing price.
Cox Aaron, the EVP, Chief Financial Officer of Horizon Therapeutics Public Limited Company, sale 36,148 shares at $113.17 during a trade that took place back on Jan 13, which means that Cox Aaron is holding 277 shares at $4,090,847 based on the most recent closing price.
Stock Fundamentals for HZNP
Equity return is now at value 11.80, with 6.50 for asset returns.